NAPLEX Question of the Week: Vaccines

Vaccines are an increasingly important part of daily practice for pharmacists, especially in the community setting. Knowing differences in dosing, timing, special populations, and storage is critical when evaluating vaccines.
NAPLEX Question of the Week: Vaccines
Like

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

YT is a 64 year old female who reports to her local independent pharmacy wishing to receive the Zoster vaccine after talking to her neighbor who recently contracted shingles. Her past medical history is significant for hypertension, hyperlipidemia, and gastroesophageal reflux disease (GERD) for which she takes lisinopril/hctz 20/12.5mg daily, atorvastatin 40mg daily, and omeprazole 20mg daily. She inquires about the newest shingles vaccine called Shingrix. Which of the following is true regarding this vaccine compared to Zostavax? Select all that apply.

A. Shingrix is a live vaccine while Zostavax is an inactivated vaccine.

B. Shingrix requires a 2-dose series while Zostavax requires only one dose

C. Shingrix requires refrigeration while Zostavax must be stored frozen

D. Shingrix's effectiveness wanes significantly over time compared to Zostavax

E. Shingrix administration would be recommended in immunocompetent patients previously vaccinated with Zostavax

Rationale:

Answers B, C, and E are correct. Shingrix does require a two dose series (Answer B) but in turn its effectiveness over time does not wane with age. Therefore Answer D is incorrect as waning over time is known with Zostavax. Storage is an important differentiator between these products (Answer C). In immunocompetent patients who have already received Zostavax, it is still recommended to administer Shingrix (Answer E). Answer A is incorrect as Zostavax is the live vaccine. This is an important differentiator between the two products as Zostavax is contraindicated in immunosuppressed patients while Shingrix is not due to being an inactivated vaccine.

The Advisory Committee on Immunization Practices (ACIP) within the CDC recently updated their overall recommendations for zoster vaccination this year: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html

Create a Free MyAccess Profile

AccessMedicine Network is the place to keep up on new releases for the Access products, get short form didactic content, read up on practice impacting highlights, and watch video featuring authors of your favorite books in medicine. Create a MyAccess profile and follow our contributors to stay informed via email updates.